vs
Side-by-side financial comparison of IDEAYA Biosciences, Inc. (IDYA) and BRC Group Holdings, Inc. (RILY). Click either name above to swap in a different company.
IDEAYA Biosciences, Inc. is the larger business by last-quarter revenue ($207.8M vs $188.3M, roughly 1.1× BRC Group Holdings, Inc.). IDEAYA Biosciences, Inc. runs the higher net margin — 57.4% vs 47.9%, a 9.4% gap on every dollar of revenue.
IDEAYA Biosciences, Inc. is a clinical-stage biotechnology company focused on oncology, developing targeted therapies and synthetic lethality treatments for patients with genetically defined cancers. It advances a pipeline of candidates across multiple tumor types, partnering with industry stakeholders to accelerate global access to innovative cancer care solutions.
IDYA vs RILY — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $207.8M | $188.3M |
| Net Profit | $119.2M | $90.3M |
| Gross Margin | — | 79.5% |
| Operating Margin | 52.2% | 32.3% |
| Net Margin | 57.4% | 47.9% |
| Revenue YoY | — | -21.9% |
| Net Profit YoY | 330.1% | 1710.8% |
| EPS (diluted) | $1.33 | $2.78 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $188.3M | ||
| Q3 25 | $207.8M | $215.3M | ||
| Q2 25 | — | $188.2M | ||
| Q1 25 | — | $197.2M | ||
| Q4 24 | — | $241.0M | ||
| Q3 24 | $0 | $225.5M | ||
| Q2 24 | $0 | $256.0M | ||
| Q1 24 | $0 | $263.4M |
| Q4 25 | — | $90.3M | ||
| Q3 25 | $119.2M | $91.1M | ||
| Q2 25 | — | $139.5M | ||
| Q1 25 | — | $-10.0M | ||
| Q4 24 | — | $-5.6M | ||
| Q3 24 | $-51.8M | $-284.4M | ||
| Q2 24 | $-52.8M | $-433.6M | ||
| Q1 24 | $-39.6M | $-49.2M |
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 83.7% | ||
| Q2 25 | — | 81.3% | ||
| Q1 25 | — | 81.4% | ||
| Q4 24 | — | 79.8% | ||
| Q3 24 | — | 82.1% | ||
| Q2 24 | — | 84.5% | ||
| Q1 24 | — | 85.3% |
| Q4 25 | — | 32.3% | ||
| Q3 25 | 52.2% | 30.4% | ||
| Q2 25 | — | 5.7% | ||
| Q1 25 | — | -31.2% | ||
| Q4 24 | — | -69.2% | ||
| Q3 24 | — | -36.4% | ||
| Q2 24 | — | -90.8% | ||
| Q1 24 | — | -6.1% |
| Q4 25 | — | 47.9% | ||
| Q3 25 | 57.4% | 42.3% | ||
| Q2 25 | — | 74.1% | ||
| Q1 25 | — | -5.1% | ||
| Q4 24 | — | -2.3% | ||
| Q3 24 | — | -126.1% | ||
| Q2 24 | — | -169.4% | ||
| Q1 24 | — | -18.7% |
| Q4 25 | — | $2.78 | ||
| Q3 25 | $1.33 | $2.91 | ||
| Q2 25 | — | $4.50 | ||
| Q1 25 | — | $-0.39 | ||
| Q4 24 | — | $-0.01 | ||
| Q3 24 | $-0.60 | $-9.39 | ||
| Q2 24 | $-0.68 | $-14.35 | ||
| Q1 24 | $-0.53 | $-1.71 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $786.9M | $226.6M |
| Total DebtLower is stronger | — | $1.4B |
| Stockholders' EquityBook value | $1.1B | $-171.5M |
| Total Assets | $1.2B | $1.7B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $226.6M | ||
| Q3 25 | $786.9M | $184.2M | ||
| Q2 25 | — | $267.4M | ||
| Q1 25 | — | $138.3M | ||
| Q4 24 | — | $146.9M | ||
| Q3 24 | $920.0M | $159.2M | ||
| Q2 24 | $701.7M | $236.9M | ||
| Q1 24 | $698.8M | $190.7M |
| Q4 25 | — | $1.4B | ||
| Q3 25 | — | $1.3B | ||
| Q2 25 | — | $1.3B | ||
| Q1 25 | — | $1.4B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $-171.5M | ||
| Q3 25 | $1.1B | $-260.5M | ||
| Q2 25 | — | $-351.7M | ||
| Q1 25 | — | $-496.8M | ||
| Q4 24 | — | $-488.2M | ||
| Q3 24 | $1.2B | $-497.6M | ||
| Q2 24 | $931.7M | $-218.3M | ||
| Q1 24 | $935.3M | $228.4M |
| Q4 25 | — | $1.7B | ||
| Q3 25 | $1.2B | $1.7B | ||
| Q2 25 | — | $1.5B | ||
| Q1 25 | — | $1.5B | ||
| Q4 24 | — | $1.8B | ||
| Q3 24 | $1.2B | $2.2B | ||
| Q2 24 | $973.7M | $3.2B | ||
| Q1 24 | $961.5M | $5.0B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $142.2M | $26.2M |
| Free Cash FlowOCF − Capex | $142.2M | — |
| FCF MarginFCF / Revenue | 68.4% | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | 1.19× | 0.29× |
| TTM Free Cash FlowTrailing 4 quarters | $13.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $26.2M | ||
| Q3 25 | $142.2M | $-60.6M | ||
| Q2 25 | — | $-25.6M | ||
| Q1 25 | — | $184.0K | ||
| Q4 24 | — | $-2.7M | ||
| Q3 24 | $-49.2M | $19.5M | ||
| Q2 24 | $-32.9M | $111.5M | ||
| Q1 24 | $-43.8M | $135.4M |
| Q4 25 | — | — | ||
| Q3 25 | $142.2M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-49.7M | — | ||
| Q2 24 | $-33.9M | — | ||
| Q1 24 | $-45.1M | — |
| Q4 25 | — | — | ||
| Q3 25 | 68.4% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | 0.29× | ||
| Q3 25 | 1.19× | -0.66× | ||
| Q2 25 | — | -0.18× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IDYA
Segment breakdown not available.
RILY
| Transferred At Point In Time | $101.4M | 54% |
| Wealth Management Segment | $30.7M | 16% |
| Corporate Finance Consulting And Investment Banking Fees | $27.1M | 14% |
| Services And Fees | $24.8M | 13% |
| Commissions Fees And Reimbursed Expenses | $4.8M | 3% |
